c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.

Cat. No.	Product name	CAS No.	Purity
T4260	Capmatinib 2HCl	1197376-85-4	100%
T4260	INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.INCB28060 exhibits picomolar enzymatic potency and is highl...
T2208	Bacitracin Zinc	1405-89-6	63.98%
T2208	Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from M...
T5677	SAR125884 hydrochlorid (1116743-46-4(free base))	T5677	95%
T5677	SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).
T39507L	Fosgonimeton acetate		97.05%
T39507L	Fosgonimeton aceate is an agonist of hepatocyte growth factor (HGF).
T6095	JNJ-38877605	943540-75-8	97.15%
T6095	JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
T3274	S49076	1265965-22-7	97.4%
T3274	S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.
T6907	NPS-1034	1221713-92-3	97.86%
T6907	NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
T7376	Dihexa	1401708-83-5	98%
T7376	Dihexa is an activator of the hepatocyte growth factor/c-Met (HGF/c-Met) system,it binds to HGF (Kd = 65 pM),and an analog of the peptide angiotensin IV.
T5656	(±)-Norcantharidin	29745-04-8	98%
T5656	Norcantharidin is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T6517	Golvatinib	928037-13-2	98%
T6517	Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-...
TQ0210	Savolitinib	1313725-88-0	98.03%
TQ0210	Savolitinib (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).
T3550	X-376	1365267-27-1	98.29%
T3550	Ensartinib (X-396) is an orally available small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with potential antineoplastic...
T5467	SAR125844	1116743-46-4	98.39%
T5467	SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)
T2676	PF-04217903	956905-27-4	98.55%
T2676	MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.
T2680	NVP-BVU972	1185763-69-2	98.61%
T2680	NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.
T4332	C-Kit-IN-1	1225278-16-9	98.72%
T4332	DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).
T1797	Cabozantinib S-malate	1140909-48-3	98.87%
T1797	Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential a...
T2282	RPI-1	269730-03-2	98.91%
T2282	RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.
T6260	AMG-208	1002304-34-8	99.12%
T6260	AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.
T13108	Pamufetinib	1190836-34-0	99.15%
T13108	TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectivel...